Exit
Register
Login
2025 MaTOS Lung | Session XII | Future Landscape on Different Genomics Drivers Biomarkers in IO and ctDNA Platforms
Novel Frontiers in KRAS Inhibition
Novel Approaches to STK11, KEAP and TP53 Co-Mutations
HER2 Inhibition: ADC-TKI-Bi-Specifics
How to Target BRAF Non-V600E
Novel Advances For Exon20ins
Biomarkers for IO Selection and Toxicity: Is this Feasible?
Role of ctDNA From Different Platforms to Escalate or De-Escalate Therapy in Lung Cancer?
Q & A Session
Finish Course
You need to enroll in this course to view this chapter
This chapter is locked
HER2 Inhibition: ADC-TKI-Bi-Specifics
Enroll for $5,000.00
0% Course Complete